Compare Davita Inc (DVA) vs MakeMyTrip Ltd (MMYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs MakeMyTrip Ltd — how do they compare? Davita Inc trades at $180 (market cap $11.38B), while MakeMyTrip Ltd trades at $60.21 (market cap $5.78B). The key difference: Davita Inc is the larger of the two by market cap, and Davita Inc is trading nearer its 52-week high, MakeMyTrip Ltd nearer its low. Which is the better fit depends on your goals.
| DVA | MMYT | |
|---|---|---|
Market Cap | $11.38B | $5.78B |
Sector | Health | Technology |
52-Week High | $240.96 | $103.21 |
52-Week Low | $103.87 | $36.30 |
Enterprise Value | $24.10B | $6.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.69, down slightly by 0.04% over the past day. The stock shows strong fundamental performance with consistent earnings beats in recent quarters, including Q2 2026 EPS of $4.02 versus $3.88 expected (Zacks Investment Research, 2026-08-04). However, technical indicators signal a bearish trend, with the price near key support at $182. Revenue growth remains steady, climbing to $13.64 billion in 2025, though net income margin dipped to 5.47%.
The outlook is mixed; analyst consensus leans bullish with a $232.25 price target (MarketBeat, 2026-08-05), but risks include reimbursement pressure and high debt levels. Investment appeal hinges on execution against guidance amid payer-mix challenges, with the current valuation offering potential upside if operational trends stabilize.
MakeMyTrip (MMYT) trades at $60.70, down 0.34% with a bullish technical signal supported by moving averages. The company reported strong Q1 2027 earnings with revenue growth in hotels and packages offsetting air-ticketing softness. Analysts maintain a 72.7% buy rating with a 34.1% upside target. Recent financials show $978M revenue and $95M net income for 2025, though 2026 projections indicate margin compression.
The stock presents growth potential driven by travel recovery and platform diversification, but faces risks from geopolitical disruptions, fuel costs, and rising debt levels. Current valuation metrics (P/E 267, P/S 6.07) suggest premium pricing requiring sustained execution. Institutional sentiment remains positive despite recent selling by Boston Common Asset Management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About MakeMyTrip Ltd
MakeMyTrip Ltd. is a leading online travel company in India, providing a comprehensive range of travel services and products, including air tickets, hotels, holiday packages, rail tickets, and bus tickets. The company operates its primary websites and mobile apps under the brands MakeMyTrip, Goibibo, and RedBus. MMYT serves as a key intermediary in India's fragmented travel market, leveraging its platform to offer convenience and competitive pricing to consumers and businesses.
Read more on MMYT →
